The hormone glucagon is secreted by the ␣-cells of the endocrine pancreas (islets of Langerhans) during fasting and is essential for the maintenance of blood glucose levels by stimulation of hepatic glucose output. Excessive production and secretion of glucagon by the ␣-cells of the islets is a common accompaniment to diabetes. The resulting hyperglucagonemia stimulates hepatic glucose production, thereby contributing to hyperglycemia of diabetes. The reduced insulin secretion in diabetes and resultant failure to suppress glucagon secretion by intra-islet paracrine mechanisms is believed to cause the hypersecretion of glucagon. Here, we report the discovery of a new mechanism by which glucagon suppresses insulin secretion. We show that glucagon, but not glucagon-like peptide 1 (GLP-1) 
T
he ␤-cells of the pancreases of individuals with type 2 diabetes fail to produce insulin in the amounts required to maintain glucose levels in the physiological range. This circumstance is due to impairments at various levels in the pathways of the metabolism of glucose by pancreatic ␤-cells and in the actions of insulin on peripheral tissues such as skeletal muscle, liver, and adipose tissue (insulin resistance). The ␤-cells of individuals with type 2 diabetes fail to sense glucose as a signal for insulin secretion and insulin gene transcription. At the physiological level, glucagon produced by the ␣-cells of the pancreatic islets acts as an antagonist of insulin actions inasmuch as glucagon stimulates hepatic glucose production as well as lipolysis and glycogenolysis by fat and skeletal muscle, respectively. Although glucagon is essential for the maintenance of plasma glucose levels during periods of fasting, elevated plasma glucagon levels in the presence of hyperglycemia are counterproductive. Plasma glucagon concentrations are elevated in type 2 diabetic individuals. The secretion of glucagon is controlled by multiple factors, including circulating intermediary metabolites, neurotransmitters, and hormones. Glucagon secretion is normally suppressed by hyperglycemia. However, this normal homeostatic suppression is lost in individuals with diabetes, inasmuch as hyperglycemia is accompanied by hyperglucagonemia, which in turn perpetuates hyperglycemia by stimulating hepatic glucose output (1, 2) .
Pancreatic ␤-cells express glucagon receptors (3) as well as receptors for the hormones glucagon-like peptide 1 (GLP-1) (4) and pituitary adenylyl cyclase-activating peptide (PACAP) (5) . Upon binding to their receptors, glucagon, GLP-1, and PACAP stimulate the formation of cAMP, resulting in an activation of protein kinase A (PKA) that phosphorylates the cAMP response element binding protein (CREB), thereby inducing the transcriptional activity of CREB. CREB is known to stimulate insulin gene transcription by binding to a cAMP response element (CRE) in the promoter of the insulin gene (6, 7) . Activation of CREB also leads to a stimulation of the expression of a repressor of cAMP-mediated gene transcription, the inducible cAMP early repressor (ICER). ICER is formed by the cAMP-mediated activation of an internal promoter (P2) within the gene-encoding isoforms of the CRE modulator (CREM) (8) . As a consequence of the internal transcription driven by P2, ICER is synthesized and consists of the DNA binding domain (bZIP) of CREM devoid of the transactivation domain and thereby acts as a repressor of cAMP-activated gene transcription. The ICER repressor binds CREs in the promoters of numerous genes and inhibits transcriptional activation by CREB (9) . Recently, ICER has been reported to reduce transcription of the human insulin gene (10) .
In this article, we show that glucagon induces the expression of ICER, which interacts with the CRE in the insulin promoter and suppresses insulin gene transcription in pancreatic ␤-cells. The induction of ICER is not seen with the hormones GLP-1 and PACAP that have receptors on ␤-cells and that also activate the formation of cAMP levels in islet cells comparable to that of glucagon. These observations suggest that glucagon specifically induces the expression of ICER in ␤-cells and that chronic hyperglucagonemia and consequent induction of ICER may represent an additional mechanism by which the production of insulin is impaired in diabetes.
and forskolin (10 µmol/l). After fixation in 4% paraformaldehyde in PBS for 10 min at room temperature and several rinses in PBS, samples were permeabilized with 100% methanol for 10 min at -20°C and then blocked with 3% normal donkey serum for 10 min at room temperature. The samples were then incubated at 4°C overnight with a nonimmune serum or a guinea pig antiserum raised against insulin (Linco Research, St. Louis, MO) or the ␣CREM S4 antiserum (16, 17) at dilutions of 1:1,000 and 1:500, respectively. After rinsing with PBS, slides were again blocked with 3% normal donkey serum for 10 min at room temperature before being localized with donkey anti-guinea pig indocarbocyanine (1:500) (Jackson Immunoresearch Laboratories, West Grove, CA) and goat anti-rabbit dichloroazinylamino fluorescein-conjugated secondary antibodies (1:200) for 30 min at room temperature. Slides were rinsed with PBS, mounted in fluorescent mounting medium (Kierkegaard & Perry Laboratories, Gaithersburg, MD), and stored in the dark. Images were obtained using a Zeiss Epi-fluorescence microscope equipped with an Optronics TEC-470 charge-coupled device camera (Optronics Engineering, Goleta, CA) interfaced with a Power Macintosh 7100 installed with IP Lab Spectrum analysis software (Signal Analytics, Vienna, VA). cAMP formation by isolated rat pancreatic islets. Isolated rat islets were treated with 0.5 mmol/l IBMX and either glucagon, GLP-1, or PACAP (10 nmol/l each) for 0 and 30 min. Thereafter, cells including media were taken up in 100% ice-cold ethanol and frozen at -80°C overnight. After thawing and lyophilization, samples were dissolved in a buffer of a cAMP enzyme-linked immunoassay kit (Assay Designs, Ann Arbor, MI). Measurements were performed according to instruction of the manufacturer. Results are given in Fig. 3C as foldinduction (mean ± SE) of cAMP between 0 and 30 min of treatment. Plasmids and cell transfection. Expression plasmids were all driven with the cytomegalovirus (CMV) promoter in the plasmid pCDNA3.1 vector (Invitrogen, La Jolla, CA). The insulin-1 gene 5Ј flanking sequences from bp -410 to +1 inserted adjacent to a firefly luciferase reporter have been described (18) . A deletion of the four central nucleotides in the CRE of the insulin promoter ( Fig. 4A ) was introduced by standard methods (19) .
INS-1 immortalized pancreatic ␤-cells (provided by C. Wolheim, University of Geneva, Switzerland, passages 99-104) were grown at 37°C in humidified 5% CO 2 -95% O 2 in RPMI (Life Technologies, Grand Island, NY) at 5.5 mmol/l glucose per liter supplemented with 10% heat-inactivated fetal calf serum, 1% HEPES buffer, pH 7.6, 1% sodium-pyruvate (Gibco-BRL), 5 µl/l ␤-mercaptoethanol (Sigma), and 100 U penicillin and 100 µg streptomycin per milliliter. Transfections were performed with Lipofectamine 2000 reagent (Gibco-BRL) according to the instructions of the manufacturer. Transfections for luciferase assays were performed in 12-well plates. There was 1 µg of the promoter/ reporter construct transfected per well. A Rous sarcoma virus (RSV)-␤-galactosidase vector was cotransfected for normalization of luciferase assays for transfection efficiency. Luciferase activity obtained after transfection was normalized to the luciferase activity obtained after transfection of the promoterless luciferase plasmid in the same experiment.
Dispersed primary rat islets were cultured in 12-well dishes in RPMI 1640 (Gibco-BRL) at 5.5 mmol glucose per liter supplemented with 10% heat-inactivated fetal calf serum and 100 U penicillin and 100 µg streptomycin per milliliter at 37°C in humidified 5% CO 2 -95% O 2 . Transfections were performed with GeneFector (Venn-Nova, Pompano Beach, FL) according to the instructions of the manufacturer using 5 µl of reagent per transfection reaction. There was 5 µg of the promoter/reporter construct transfected per well. An RSV-␤-galactosidase vector (1 µg) was cotransfected for normalization of luciferase assays for transfection efficiency. Transfection was performed in culture medium lacking serum and antibiotics/antimycotics for 4 h. Thereafter, an equal amount of medium with twice the concentration of serum and antimicrobial agents was added to each culture well. At this time, cells were treated with GLP-1, PACAP, or glucagon at a concentration of 10 nmol/l each. Cells were harvested after 12 h for measurements of reporter activities. Luciferase activity obtained after transfection was normalized to the background luciferase activity obtained after transfection of the promoterless luciferase plasmid in the same experiment. ICER antisense RNA experiments. INS-1 cells were transfected with fulllength ICER cDNA inserted in the antisense (AS) orientation into plasmid pcDNA 3.1 (pcDNA ICER-AS) together with the -410-bp insulin promoter/luciferase reporter plasmid using Lipofectamine 2000. Transfection efficiency, as assessed by transfecting a CMV-EGFP (enhanced green fluorescent protein; Clontech, La Jolla, CA) vector and visualizing under a microscope equipped with an appropriate fluorescent light source, was 80% (data not shown). At 48 h after cotransfection of pcDNA ICER-AS, cells were harvested and extracted, ICER and CREB were assessed by Western immunoblot, and insulin promoter activity was measured by luciferase assays. Electrophoretic mobility shift assays. Synthetic oligonucleotides corresponding to the CRE within the rat insulin-1 gene promoter were annealed, endlabeled with 32 P with T4 polynucleotide kinase, and purified over a Sephadex G-50 spin column (Boehringer Mannheim, Nutley, NJ). Electrophoretic mobility shift assays (EMSAs) were performed by incubating ~5 ϫ 10 4 cpm of endlabeled DNA probe (0.02-0.03 ng DNA) with glutathione S-transferase (GST) fusion proteins in a binding buffer (10 mmol/l Tris-HCl [pH 8.0], 40 mmol/l KCl, 6% glycerol, 1 mmol/l dithiothreitol, and 0.05% Nonidet P-40) for 20-30 min at room temperature. The reaction mixture was analyzed by electrophoresis on a 6% nondenaturing polyacrylamide gel. After electrophoresis, the gel was dried and exposed to X-ray film for 6-72 h. The recombinant GST-CREB and GST-ICER plasmids have been described previously (17) .
Statistical analysis. Student's t test was performed with StatView software. A P value of <0.05 was considered statistically significant.
RESULTS
Induction of ICER mRNA and protein by forskolin and IBMX in rat islets. After culture overnight, isolated rat islets were incubated with IBMX and forskolin and harvested for analyses of amounts of ICER mRNA by RT-PCR at different time points. ICER mRNA is detected at basal conditions and is induced with IBMX and forskolin with a maximum induction at 4-8 h, after which ICER mRNA levels decrease (Fig. 1A) . These findings of a biphasic expression of ICER mRNA in response to elevations in cAMP induced by IBMX plus forskolin are in accordance with results observed earlier in studies of rat testes and hypothalamus (15, (20) (21) (22) . Changes in insulin mRNA levels by RT-PCR were not detectable in any of the experiments, likely owing to the long half-life of pro-insulin mRNA of >24 h (23) (data not shown).
To determine whether the induction of ICER mRNA also results in a change in ICER protein levels in pancreatic islets, rat islets were incubated with forskolin plus IBMX for various times. Protein extracts were prepared from the islets and were examined by Western immunoblots. The results show that ICER protein is induced with a time course similar to the induction of ICER mRNA. Furthermore, the induction of ICER protein in response to elevated cAMP induced by IBMX plus forskolin reaches a maximum concentration at 8 h; thereafter, levels of ICER protein diminish (Fig. 1B) .
To assess whether ICER is induced in the pancreatic ␤-cells of the rat islets that produce insulin, dispersed rat pancreatic islet cells were prepared, treated with ICER, and subjected to in situ double immunostaining for insulin and ICER. The forskolin treatment of dispersed islet cells results in a marked induction of ICER in the nuclei of ␤-cells (Fig. 2) . The antiserum used to detect ICER would also detect longer CREM isoforms, if present. However, we have not been able to detect any longer CREM isoforms in rat islets by either RT-PCR (data not shown) or Western immunoblot (Fig. 1) . Double immunostaining with anti-insulin and anti-ICER sera shows that the majority of cells that express ICER immunoreactivity in their nuclei after treatment with forskolin are insulin-producing ␤-cells. However, a small number of cells that do not stain for insulin do stain for ICER (data not shown), suggesting that the expression of ICER in pancreatic islets is not restricted to pancreatic ␤-cells (Fig. 2) . Stimulation of the induction of ICER mRNA in rat islets by glucagon but not by GLP-1 or PACAP. Having demonstrated that ICER is expressed in rat islet ␤-cells in response to forskolin, we sought to determine the physiologic relevance of this finding. At least three hormones that increase cellular levels of cAMP have G s␣ -coupled receptors on ␤-cells, glucagon, GLP-1, and PACAP and are known to be important physiological regulators of ␤-cell functions (5,13). Therefore, aliquots of rat islets were individually incubated with IBMX and with these hormones at concentrations of 10 nmol/l. Remarkably, only glucagon, and neither GLP-1 nor PACAP, induced ICER mRNA (Fig. 3A) . This effect of glucagon to induce ICER expression was also seen at ambient glucose levels of 5.5 mmol/l (data not shown) as well as 11.1 mmol/l. This latter glucose concentration was chosen to unmask possible actions of GLP-1 at higher glucose levels (glucose-dependent effects of GLP-1) (13) . A time course experiment showed induction of ICER mRNA as early as 6 h after incubation of rat islets with glucagon, and increased ICER mRNA was detected by RT-PCR until 12 h (data not shown). This unexpected finding of the induction of ICER mRNA by glucagon but not GLP-1 or PACAP prompted an examination of cAMP formation in rat islets in response to these hormones. Surprisingly, glucagon, GLP-1, and PACAP all activated the formation of cAMP equivalently by 30-to 40-fold (Fig. 3C) . Thus, glucagon, GLP-1, and PACAP all elevate cAMP levels, and GLP-1 and PACAP stimulate insulin gene transcription in rat islets, as has been shown before (5), but glucagon is unique among these three hormones in the activation of ICER expression. Induction of ICER inhibits insulin promoter activity in INS-1 cells. Because ICER is a known repressor of cAMPmediated gene transcription (8) and the rat insulin-1 gene contains a CRE in its promoter (6,7), we carried out experiments to determine whether ICER represses the cAMP-activated transcription of the rat insulin gene. The actions of ICER on the transcriptional expression of the insulin gene were examined in transient cotransfection experiments of INS-1 cells with a recombinant insulin promoter/reporter and a PKA expression plasmid vector (Fig. 4) . Cotransfection of the expression vector encoding the catalytic subunit of PKA (PKAc) with the -410-bp insulin promoter/luciferase vector reporter shows that PKA stimulates transcription from the -410-bp insulin promoter (Fig. 4B) . Deletion of the central four nucleotides (ACGT) of the insulin promoter CRE results in a reduction in basal luciferase activity by ~40%, as shown previously (24) (data not shown). Cotransfection of the PKAc expression vector with the CRE-mutated promoter/reporter vector did not activate the -410-bp insulin promoter/reporter gene. Cotransfection of CMV-CREB and PKAc in combination further increases insulin gene transcription (Fig. 4C) .
It is important to note the dose-dependency of the PKAc expression vector on stimulation of the -410-bp rat insulin promoter/reporter (Fig. 4B) . For the experiments in Fig. 4C , PKAc was transfected at a dose that only led to a significant activation of the insulin reporter when an expression vector for CREB was cotransfected. Coexpression of ICER with the -410-bp insulin-1 promoter/luciferase reporter inhibited the enhancement of insulin gene expression mediated by CREB plus PKAc (Fig. 4C) . Moreover, overexpression of ICER in pancreatic ␤-cells leads to a decrease in the basal insulin promoter activity reported by the -410-bp insulin/luciferase plasmid vector (Fig. 4D) .
RT-PCR analysis of several pancreatic insulin-producing ␤-cell lines (INS-1, RIN, and ␤TC-3) revealed a constitutive expression of ICER that could not be further stimulated by forskolin/IBMX (data not shown). This finding may explain why such a large dose of ICER expression plasmid was needed to reduce activity of the -410-bp insulin/luciferase plasmid reporter in INS-1 cells (Fig. 4D) . ICER AS-RNA expression inhibits ICER production and increases insulin promoter activity. We next sought to investigate the effects of reducing endogenous ICER protein levels in INS-1 cells on insulin/luciferase plasmid reporter activity. We used an AS-RNA approach to knock down ICER production in INS-1 cells. Full-length ICER AS-RNA expression by transfection in INS-1 cells reduced ICER but not CREB to undetectable levels, as assessed by Western immunoblot (Fig. 5 ). This result was accompanied by a statistically significant increase in the activity of the -410-bp insulin promoter/luciferase reporter (Fig. 5A) . The same experiment conducted with a reporter plasmid with a mutated CRE within the insulin promoter showed no effect of reduced ICER protein. A cotransfected RSV-␤-galactosidase vector was used to normalize the luciferase levels but also to control for nonspecific effects of the ICER-AS plasmid on generalized gene expression. Neither the level of CREB (Fig. 5) nor the ␤-galactosidase activity (data not shown) was affected by the ICER-AS plasmid, indicating a specific effect of the ICER-AS approach. Glucagon inhibits insulin promoter activity in rat islet cells. To determine whether glucagon, which induces ICER production in rat islets, also leads to a downregulation of the insulin transcription rate (as found in the transient transfection experiments in INS-1 cells), dispersed primary rat islet cells were transfected with the -410 rat insulin promoter/reporter plasmid and treated with one of the following solutions for 12 h: vehicle alone, GLP-1, PACAP, or glucagon (all at 10 nmol/l concentrations). Using the rat insulin promoter ensured that the effects being measured would be specific to ␤-cells in the dispersed islet cell culture. Whereas both GLP-1 (P < 0.05) and PACAP (NS) increased insulin transcription rates as reflected by increased relative luciferase activity, glucagon treatment led to a reduced insulin transcription rate (P < 0.05) (Fig. 6 ). ICER and CREB bind to the insulin promoter CRE. To determine whether ICER interacts with the insulin CRE directly, EMSAs were performed on the labeled rat insulin CRE and GST-ICER and GST-CREB. The results of the EMSAs show that both CREB and ICER bind to the insulin promoter CRE (Fig. 7) .
DISCUSSION
Here we demonstrate the induction of ICER by glucagon and forskolin in pancreatic islets (␤-cells). Further, we show that ICER-by binding to the CRE-reduces the activation of the insulin gene promoter in the clonal pancreatic ␤-cell line INS-1 (10), and reduction of ICER expression in INS-1 cells increases insulin promoter/reporter activity. Using a rat insulin-I luciferase reporter, we demonstrate that glucagon, but not GLP-1 or PACAP, reduces insulin gene transcription in dispersed primary rat ␤-cells.
Hyperglucagonemia, which characteristically occurs in diabetes, is considered to constitute a major factor contributing to the metabolic disturbances in both types 1 and 2 diabetes (1,2). The elevated plasma levels of glucagon increase hepatic glucose output resulting in further elevated fasting glucose levels and a resistance to the actions of insulin (2) . Diabetes manifests by a deficiency of the pancreatic ␤-cells in producing insulin in the amounts required to meet the body's needs. The reduced insulin production characteristic of diabetes is believed to be due to impaired expression of the insulin gene. factor (HNF)-1␣, HNF-1␤, HNF-4␣, and ␤2/NeuroD, result in impaired insulin production in early-onset forms of diabetes known as maturity-onset diabetes of the young (MODY) (25) . Prolonged hyperglycemia exerts toxic effects on ␤-cells (socalled glucose toxicity) and has been shown to reduce the expression of the transcription factors RIPE3b1 and IPF-1 (26, 27) , which are required for proper regulation of insulin gene transcription and inducement of the expression of the transcription factor CCAAT/enhancer binding protein ␤, an inhibitor of insulin gene transcription (18, 28) .
The results of our study support the idea that the induction of the cAMP-inducible transcriptional repressor ICER may be an additional mechanism by which insulin gene transcription is impaired in the context of hyperglucagonemia, as occurs in diabetes. Glucagon appeared to be relatively specific in the induction of ICER in ␤-cells. The hormones GLP-1 and PACAP also stimulated cAMP formation in pancreatic ␤-cells (29,30) but failed to stimulate ICER gene expression. Our findings suggest that glucagon activates signaling pathways in pancreatic ␤-cells that are distinct from the cAMP signaling pathway because glucagon, GLP-1, and PACAP all increase ␤-cell levels of cAMP to comparable levels. Yet only glucagon, and not GLP-1 or PACAP, induces the expression of the ICER repressor, which downregulates insulin promoter activity. Alternatively, therefore, GLP-1 and PACAP may activate additional signal pathways that inhibit cAMPmediated induction of ICER expression. Thus, it appears that the intracellular effects of glucagon, GLP-1, and PACAP differ with regard to the formation of ICER and consequent inhibition of insulin gene transcription.
Several caveats regarding our findings are worth noting. Glucagon (31, 32) , GLP-1 (33) (34) (35) (36) , and PACAP (5) tors, even in a situation in which cAMP may be generated by each receptor upon binding of its cognate ligand. Thus, it is unclear which intracellular pathway is involved in the apparent selective effect of glucagon on ICER expression in pancreatic ␤-cells. To this end, further studies will be necessary to elucidate the differences in intracellular signaling in pancreatic ␤-cells.
To assess the functional significance of ICER on insulin gene expression, we conducted transient experiments in INS-1 cells (Fig. 3) . It is important to note here that the pathway we used to stimulate the insulin reporter gene with PKA may not necessarily reflect the physiological signal transduction pathway of glucagon in pancreatic ␤-cells. Rather, we have sought to use a system that, in vitro, reflects enhanced insulin gene transcription through activation by phosphorylated CREB to then study the effect of superimposed overexpression of ICER. Because 1) glucagon treatment increases ICER expression in pancreatic ␤-cells and 2) ICER downregulates insulin promoter activity in INS-1 cells, we next determined whether glucagon treatment reduces insulin transcription in primary rat ␤-cells and knockdown of ICER increases insulin promoter/reporter activity in INS-1 cells. Indeed, knockdown of ICER by way of the AS approach led to increased insulin promoter/reporter activity in INS-1 cells (Fig. 5) . Further, dispersed rat islet cells treated with glucagon have a reduced rate of insulin transcription, as assessed by a rat insulin-I promoter/luciferase reporter plasmid (Fig. 6 ).
CREB and/or CREB-like factors have been proposed to activate the cAMP-activated response elements (CAREs) of the ICER promoter, but a direct demonstration of such activation has not been accomplished. CREB is known to be activated by phosphorylation of serine-133 not only by PKA (38) but by several other protein kinases, e.g., CREB kinase (39), calcium-calmodulin kinase (40, 41) , mitogen-activated protein kinase (42) (43) (44) , and Akt/PKB kinase (45) . Furthermore, GLP-1 and PACAP are hormones that are known to augment insulin secretion from ␤-cells during periods of nutrient intake (feeding) (5, 13) , whereas glucagon secretion is suppressed during feeding and acts during periods of nutrient deprivation to mobilize glucose from stores in liver, muscle, and fat essential to maintain blood glucose levels (1, 2) . Thus, in a physiological sense, glucagon should suppress the secretion and production of insulin during fasting to prevent hypoglycemia due to unwanted hypoglycemic actions of insulin during fasting. ICER is expressed by the CREM gene, and its expression is believed to be induced by the binding of phosphorylated CREB and/or CREB-like proteins to a cassette of four CAREs that reside within an internal promoter (P2) within the CREM gene (8, 9, 46) . ICER binds to and represses transcription from CREs of target genes and thus reduces expression of genes that are initially positively transactivated by CREB. ICER feeds back and represses its own induction through interaction with the CAREs within its own promoter. Under conditions of sustained activation of CREB, ICER mRNA and protein cycle through phases of expression and self-repression. The observations of our study are in accord with this concept of self-limited expression of ICER mRNA and protein.
Recently, Inada et al. (10) have demonstrated that CREM isoforms are also present in rat islet cells and that certain CREM isoforms positively transactivate insulin gene transcription, whereas ICER, another product of the CREM gene, inhibits the transactivation. By RT-PCR, we attempted to detect longer CREM isoforms in primary rat islets and failed to detect any product. We were able to detect only ICER consistently as a product of the CREM gene in rat islets. This result is in accord with the Western immunoblot of rat islet protein extracts, which shows only ICER immunoreactivity and no higher molecular weight immunoreactivity, suggesting the presence of longer CREM isoforms. One reason for the discrepancy between our data and those of Inada et al. is that Inada et al. may have detected CREM isoforms in immortalized rat insulinoma cells (RIN), which may express a wider variety of CREM isoforms not present at significant levels in rat islets.
In the context of diabetes, it seems unlikely that sustained hyperglucagonemia, by virtue of inducing a cyclical expression of ICER, may by itself lead to a reduced expression of the insulin gene. But together with additional factors, such as mutations in transcription factors regulating insulin gene expression or the consequences of glucose toxicity on pancreatic ␤-cells, the induction of the cAMP-inducible repressor ICER in response to hyperglucagonemia may present an additional mechanism contributing to dysregulated insulin gene expression and synthesis.
The CRE of the insulin gene binds CREB (6, 7, 47) and confers basal activity but has relatively weak cAMP responsiveness compared with the CREs of the promoters of the glucagon and somatostatin genes (48) . In addition, the CRE of the insulin gene is not activated, as in pancreatic ␣-cells, by membrane depolarization or calcium influx (49) (50) (51) . Sequence comparison of the CREs of the insulin gene promoter with those of somatostatin and glucagon gene promoters reveals an atypical sequence at the 3Ј end of TGACGTCC (the C at the 3Ј end is atypical for the conserved CRE sequence TGACGTCA). Recently, Oetjen et al. (7) showed that at its 3Ј end, the insulin CRE overlaps with a CAAT motif, which binds the ubiquitous transcription factor NF-Y. NF-Y confers basal activity of the insulin gene promoter, and presence of NF-Y attenuates the cAMP response of the insulin promoter CRE. This attenuation of the cAMP response of the insulin gene promoter is further supported by the observation that when the insulin CRE is mutated into a classic CRE and the NF-Y binding site is abolished, the cAMP response of the insulin gene is markedly enhanced (7) . In this regard, the weak effect of CREB on activating the rat insulin-1 gene promoter further allows the effects of ICER as a suppressor to have a discernible effect on insulin expression. An additional possibility for ICER to have an inhibitory effect on CREB-mediated insulin gene transactivation would be by a higher affinity of ICER to the insulin CRE than CREB. However, by using off-rate analyses, we have been unable to demonstrate a difference in binding affinities of CREB and ICER on the insulin CRE (data not shown).
As part of the CREM gene, ICER may have additional effects on pancreatic ␤-cell biology. The CREM gene has been attributed a role in the regulation of cell proliferation and regeneration (52) (53) (54) . In the homozygous CREM-null mouse, liver regeneration is impaired, implicating CREM gene products in the regulation of tissue regeneration (52) . In drawing analogies to this concept, it is conceivable that the induction of ICER by glucagon or other factors within the ␤-cell may be part of a genetic program enabling proliferation of pancreatic ␤-cells (or precursors) in an attempt to augment ␤-cell mass to compensate for the relative insulin deficiency in type 2 diabetes (55) . DIABETES 
